drugset / Trial / NCT05117177
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
A2A-004 is a three-part multicenter, open-label, Phase I clinical trial intended to evaluate the safety and tolerability, and the pharmacokinetics (PK) and food effect of new formulations of inupadenant (formerly known as EOS100850), in participants with advanced solid tumors.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2024-05-09
- Completion
- 2024-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | inupadenant | Small molecule | — | Oral |